Previous close | 2.2500 |
Open | 2.2500 |
Bid | 3.1000 |
Ask | 7.5000 |
Strike | 16.00 |
Expiry date | 2024-06-21 |
Day's range | 2.2500 - 2.2500 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.